Vera Therapeutics
VERA
179 hedge funds and large institutions have $1.53B invested in Vera Therapeutics in 2025 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 73 increasing their positions, 47 reducing their positions, and 32 closing their positions.
262% more call options, than puts
Call options by funds: $17.2M | Put options by funds: $4.75M
55% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 47
3% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 32
1% more funds holding
Funds holding: 178 → 179 (+1)
0.48% less ownership
Funds ownership: 99.36% → 98.88% (-0.48%)
40% less funds holding in top 10
Funds holding in top 10: 10 → 6 (-4)
42% less capital invested
Capital invested by funds: $2.66B → $1.53B (-$1.13B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$45.8M |
| 2 |
DM
Deerfield Management
New York
|
+$33.7M |
| 3 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$30.3M |
| 4 |
CC
Commodore Capital
New York
|
+$19.4M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$12.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
-$60.8M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$37M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$32.3M |
| 4 |
SC
Samlyn Capital
New York
|
-$22M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$20.8M |
VERA Hedge Fund Activity: Q1 2025 in Review
179 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Vera Therapeutics (VERA) for Q1 2025, worth a combined $1.53B — down 42% from $2.66B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new VERA positions and 32 closed out — a net gain of 1 holder — while 73 added to existing stakes and 47 trimmed.
The largest buyer was Vestal Point Capital, adding an estimated $45.8M. The largest seller was Paradigm Biocapital Advisors, exiting entirely with an estimated $60.8M sold.
- 179 institutional investors held Vera Therapeutics (VERA) as of Q1 2025, up from 178 in Q4 2024.
- Funds reported $1.53B of Vera Therapeutics stock for Q1 2025, down 42% quarter-over-quarter.
- 33 funds opened new Vera Therapeutics positions in Q1 2025 and 32 closed out, a net change of +1 holder.
- The largest Vera Therapeutics buyer in Q1 2025 was Vestal Point Capital, an estimated $45.8M added.
- The largest Vera Therapeutics seller in Q1 2025 was Paradigm Biocapital Advisors, an estimated $60.8M sold.
Based on aggregated 13F filings for Q1 2025.